When to perform next-generation sequencing test in patients with cancer? ESMO updates its recommendations
NGS testing is now recommended also for patients with some rare tumours and to detect tumour-agnostic alterations
New insights into the evolutionary pattern of breast cancer
A more detailed picture of breast cancer establishment may facilitate prevention and detection in women at high risk
Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Cancer Research
Use of ctDNA as a surrogate in early clinical drug development – nearing its end point?
Several key issues including standardisation and validation of ctDNA response criteria for predicting clinical outcomes in oncology still need to be addressed
Can ctDNA predict outcomes in early phase trials?
Baseline and on-treatment changes in ctDNA may provide an early indication of response to experimental therapies
Challenges in cell-based immunotherapies create opportunities for progress
According to the 2023 ESMO Immuno-Oncology Awardee, Steven A. Rosenberg, the keys to progress are identifying the optimal characteristics of antitumour effector lymphocytes, cancer antigen identification and strategies for overcoming resistance mechanisms to enhance immune-cell function
Updated hallmarks of cancer guide treatment development
Old and emerging traits of cancer provide a common set of principles that may help research shape future progress
TIL therapy – an opportunity for a few centres?
Regulatory, practical and economic challenges are associated with implementing this personalised treatment on a larger scale, thus currently limiting its availability and accessibility to patients
Clonal haematopoiesis in the tumour microenvironment is an indicator of poor prognosis in NSCLC
Results from the TRACERx study suggest a potential role of CHIP as a prognostic biomarker, but further research is needed
Single-cell DNA sequencing confirms considerable intratumoural heterogeneity in breast cancer
The study involved patients with HR-positive/HER2-negative localised disease, but additional analyses are required to describe implications for clinical practice.